Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 08, 2014; 82 (10 Supplement) May 01, 2014

Monotherapy with THC/CBD Spray in Multiple Sclerosis Induced Spasticity (P7.249)

Juergen Koehler, Walter Poellmann, Wolfgang Walter Feneberg, Martin Meier
First published April 9, 2014,
Juergen Koehler
1Behandlungszentrum Kempfenhausen Berg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Poellmann
2Marianna-Strauss-Klinik Muenchen Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Walter Feneberg
3Marianne Strauss Klinik Berg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Meier
3Marianne Strauss Klinik Berg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Monotherapy with THC/CBD Spray in Multiple Sclerosis Induced Spasticity (P7.249)
Juergen Koehler, Walter Poellmann, Wolfgang Walter Feneberg, Martin Meier
Neurology Apr 2014, 82 (10 Supplement) P7.249;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: THC/CBD spray is approved for add-on therapy in multiple sclerosis (MS) induced spasticity. In this observational study we proved efficacy and side effects of a monotherapy in a clinical setting. BACKGROUND: Pivotal trial data suggested a 30% - benefit measured by a numeric rating scale (NRS) with mean intake of 8 sprays/day. The responder rate to THC/CBD was about 51% of treated patients. DESIGN/METHODS: In all MS patients treated with THC/CBD monotherapy from Sept 2011 to June 2013 Expanded disability status scale (EDSS), Ashworth scale (AS) of the upper (UE) and lower extremities (LE) and minimal muscle strength (MMS) of UE and LE were documented before treatment. NRS dosages, side effects and drop-outs with THC/CBD were analyzed. RESULTS: In 37 patients THC/CBD monotherapy was started in 37 MS patients. Mean NRS of the 28 responder was 6.9 before and 3.4 with THC/CBD, mean dosage was 4.2 sprays/day. The AS was 0.5 of the UE and 2.0 of the LE, EDSS was 6.9, MMS was 3.2 (UE) and 1.6 (LE). The 9 non-responder reported an NRS of 6.4 before and 5.4 with THC/CBD, showed an AS of 0.9 (UE) and 2.7 (LE), EDSS of 6.4, MMS of 3.4 (UE) and 1.8 (LE). Non-responder stopped because of unsatisfied efficacy (4), incontinence (1), fatigue (1), oral discomfort (2), increasing weakness (1). CONCLUSIONS: In our observational study of THC/CBD monotherapy, due to not tolerable side effects under previously given antispastic drugs a high responder rate of 76% was found. Four patients (11%) stopped treatment because of adverse events. The efficacy, measured by NRS showed a 51% reduction with a mean dosage of 4.2 sprays/day without increased weakness. The four patients who had no sufficient efficacy did not titrate dosages up to 12 sprays because of side effects. In our study THC/CBD monotherapy was well tolerated and showed a high responder rate. Further studies should be done to validate our findings.

Disclosure: Dr. Koehler has received personal compensation for activities with Almirall Hermal, Bayer Pharmaceuticals Corp., Biogen Idec, Genzyme Corp., Merck Serono, Novartis, Sanofi-Aventis Pharmaceuticals, Inc., and Teva Neuroscience. Dr. Poellmann has nothing to disclose. Dr. Feneberg has nothing to disclose. Dr. Meier has nothing to disclose.

Thursday, May 1 2014, 3:00 pm-6:30 pm

  • Copyright © 2014 by AAN Enterprises, Inc.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise